PREMARKET MOVERS: EYES ON OCCULOGIX
While a trial of a new treatment for a major cause of adult vision loss yielded
no significant improvements for the patients, the results had a huge impact
on the shares of the two companies behind the study. Shares of OccuLogix Inc.
and TLC Vision Corp. went into free fall in heavy premarket electronic trading
Friday, after the companies released an analysis of the data from the recently
completed clinical trial.
The Houston Chronicle